GlassScriptPhysician profile
Michael J Hayden
NPI 1770512766
$12,035.78
in general payments reported to CMS, 2019-2025
45 companies · $1,922 in 2025
The $1,922 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $1,132 · 2021: $1,900 · 2022: $1,773 · 2023: $2,064 · 2024: $2,136 · 2025: $1,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,121.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,400.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,375.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,263.43 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,161.72 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $917.08 | 2019-2024 | Xarelto |
| Abbott Laboratories | $753.19 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $709.04 | 2019-2024 | |
| Glaxosmithkline, LLC. | $689.41 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.44 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $439.67 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Abbvie INC. | $272.68 | 2021-2025 | |
| Amgen INC. | $241.95 | 2020-2025 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $232.20 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $202.95 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $188.00 | 2019-2025 | Eliquis, Camzyos |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hayden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.